Studies have shown that BA can activate or suppress the FXR and well known for the treatment of metabolic disorder 71 Overexpression studies with hepatic FATP5 have shown that they not only enhance the LCFA uptake 53 but also activates the primary bile precursors 72. Here, SLC27A5 is linked to metabolic disease.